Molecular and Cellular Biochemistry

, Volume 381, Issue 1–2, pp 95–103 | Cite as

Clinical significance of CD146 and latexin during different stages of thyroid cancer

Article

Abstract

Molecular mechanisms underlying thyroid tumorigenesis and identifying new therapeutic targets are still under investigation. We aim to investigate the role of CD146 and latexin (Lxn) and examine whether they have any clinical significance in thyroid cancer. Human thyroid papillary (PTC), follicular (FTC), anaplastic (ATC) cancer cells, and other control cells were used in this study. Western blot, cell proliferation, invasion assay, and shRNA were applied to study the expression levels and functional significances of CD146 and Lxn in thyroid cells. The protein expression was evaluated by immunohistochemistry using human tissue microarray (TMA) slides. Multivariate analysis was used to examine whether these proteins have any clinical significance in patients with thyroid cancer. The protein expressions of CD146 and Lxn were detected in most thyroid cancer cell lines when compared with normal cells. Notably, knockdown of CD146 reduced the migration and invasion in K1 (PTC) and OCUT-1 (ATC) cells. TMAs showed more immunoreactivity against CD146 and Lxn in PTC cores compared with FTC, ATC, and normal tissues. A positive correlation was established between CD146 and both Lxn (r = 0.421, p = 0.045) and age (r = 0.566, p = 0.012); however, it showed a negative correlation with tumor stage (r = −0.231, p = 0.010). In conclusion, CD146 and Lxn increased tumor migration and invasion in vitro and showed a high expression in PTC compared to those in ATC and normal human tissues demonstrating their role in early stage of thyroid tumorigenesis. CD146 was positively correlated with age, but negatively correlated with tumor stage.

Keywords

Thyroid cancer cells CD146 Latexin Tissue microarray Cell migration 

References

  1. 1.
    Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 83:2638–2648PubMedCrossRefGoogle Scholar
  2. 2.
    Altekruse SF KC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, et al (eds). SEER Cancer Statistics Review, 1975–2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010
  3. 3.
    Brzezianska E, Pastuszak-Lewandoska D (2011) A minireview: the role of MAPK/ERK and PI3 K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci 16:422–439PubMedCrossRefGoogle Scholar
  4. 4.
    Makita N, Iiri T (2013) Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23:151–159PubMedCrossRefGoogle Scholar
  5. 5.
    Johnson JP, Rummel MM, Rothbacher U, Sers C (1996) MUC18: a cell adhesion molecule with a potential role in tumor growth and tumor cell dissemination. Curr Top Microbiol Immunol 213(Pt 1):95–105PubMedCrossRefGoogle Scholar
  6. 6.
    Anfosso F, Bardin N, Vivier E, Sabatier F, Sampol J, Dignat-George F (2001) Outside-in signaling pathway linked to CD146 engagement in human endothelial cells. J Biol Chem 276:1564–1569PubMedCrossRefGoogle Scholar
  7. 7.
    Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY, Mancuso P, Sampol J, Solovey A, Dignat-George F (2005) Circulating endothelial cellsBiomarker of vascular disease. Thromb Haemost 93:228–235PubMedGoogle Scholar
  8. 8.
    Khan SS, Solomon MA, McCoy JP Jr (2005) Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64:1–8PubMedGoogle Scholar
  9. 9.
    Shih LM, Hsu MY, Palazzo JP, Herlyn M (1997) The cell–cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol 151:745–751PubMedGoogle Scholar
  10. 10.
    Imbert AM, Garulli C, Choquet E, Koubi M, Aurrand-Lions M, Chabannon C (2012) CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in epithelial to mesenchymal transition. PLoS ONE 7:e43752PubMedCrossRefGoogle Scholar
  11. 11.
    Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, Feng J, Yang D, Fu L, Yan X (2012) CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 109:1127–1132PubMedCrossRefGoogle Scholar
  12. 12.
    Arimatsu Y (1994) Latexin: a molecular marker for regional specification in the neocortex. Neurosci Res 20:131–135PubMedCrossRefGoogle Scholar
  13. 13.
    Hatanaka Y, Uratani Y, Takiguchi-Hayashi K, Omori A, Sato K, Miyamoto M, Arimatsu Y (1994) Intracortical regionality represented by specific transcription for a novel protein, latexin. Eur J Neurosci 6:973–982PubMedCrossRefGoogle Scholar
  14. 14.
    Liu Q, Yu L, Gao J, Fu Q, Zhang J, Zhang P, Chen J, Zhao S (2000) Cloning, tissue expression pattern and genomic organization of latexin, a human homologue of rat carboxypeptidase A inhibitor. Mol Biol Rep 27:241–246PubMedCrossRefGoogle Scholar
  15. 15.
    Pallares I, Bonet R, Garcia-Castellanos R, Ventura S, Aviles FX, Vendrell J, Gomis-Ruth FX (2005) Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc Natl Acad Sci USA 102:3978–3983PubMedCrossRefGoogle Scholar
  16. 16.
    Callahan G, Hartmann, L, Smith, D (1999) Characterization of a carboxypeptidase—A inhibitor identified by DD-PCR in primary ovarian tumors and cell lines. Faseb J f 637Google Scholar
  17. 17.
    Van Zant G, Liang Y (2009) Natural genetic diversity as a means to uncover stem cell regulatory pathways. Ann N Y Acad Sci 1176:170–177PubMedCrossRefGoogle Scholar
  18. 18.
    Liang Y, Van Zant G (2008) Aging stem cells, latexin, and longevity. Exp Cell Res 314:1962–1972PubMedCrossRefGoogle Scholar
  19. 19.
    Nada AS, Hawas AM, Amin Nel D, Elnashar MM, Abd Elmageed ZY (2012) Radioprotective effect of Curcuma longa extract on gamma-irradiation-induced oxidative stress in rats. Can J Physiol Pharmacol 90:415–423PubMedCrossRefGoogle Scholar
  20. 20.
    McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses—correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716–721PubMedGoogle Scholar
  21. 21.
    Liu D, Hou P, Liu Z, Wu G, Xing M (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69:7311–7319PubMedCrossRefGoogle Scholar
  22. 22.
    Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, Liu Q, Mann K, Bader BL (2003) A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102:184–191PubMedCrossRefGoogle Scholar
  23. 23.
    Vleminckx KL, Deman JJ, Bruyneel EA, Vandenbossche GM, Keirsebilck AA, Mareel MM, van Roy FM (1994) Enlarged cell-associated proteoglycans abolish E-cadherin functionality in invasive tumor cells. Cancer Res 54:873–877PubMedGoogle Scholar
  24. 24.
    Hedrick L, Cho KR, Boyd J, Risinger J, Vogelstein B (1992) DCC: a tumor suppressor gene expressed on the cell surface. Cold Spring Harb Symp Quant Biol 57:345–351PubMedCrossRefGoogle Scholar
  25. 25.
    Lehmann JM, Riethmuller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86:9891–9895PubMedCrossRefGoogle Scholar
  26. 26.
    Vainio O, Dunon D, Aissi F, Dangy JP, McNagny KM, Imhof BA (1996) HEMCAM, an adhesion molecule expressed by c-kit + hemopoietic progenitors. J Cell Biol 135:1655–1668PubMedCrossRefGoogle Scholar
  27. 27.
    Tanaka H, Matsui T, Agata A, Tomura M, Kubota I, McFarland KC, Kohr B, Lee A, Phillips HS, Shelton DL (1991) Molecular cloning and expression of a novel adhesion molecule, SC1. Neuron 7:535–545PubMedCrossRefGoogle Scholar
  28. 28.
    Pourquie O, Corbel C, Le Caer JP, Rossier J, Le Douarin NM (1992) BEN, a surface glycoprotein of the immunoglobulin superfamily, is expressed in a variety of developing systems. Proc Natl Acad Sci USA 89:5261–5265PubMedCrossRefGoogle Scholar
  29. 29.
    Burns FR, von Kannen S, Guy L, Raper JA, Kamholz J, Chang S (1991) DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron 7:209–220PubMedCrossRefGoogle Scholar
  30. 30.
    Bu P, Zhuang J, Feng J, Yang D, Shen X, Yan X (2007) Visualization of CD146 dimerization and its regulation in living cells. Biochim Biophys Acta 1773:513–520PubMedCrossRefGoogle Scholar
  31. 31.
    Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M (2008) Isolation and characterization of CD146 + multipotent mesenchymal stromal cells. Exp Hematol 36:1035–1046PubMedCrossRefGoogle Scholar
  32. 32.
    Covas DT, Panepucci RA, Fontes AM, Silva WA Jr, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA (2008) Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146 + perivascular cells and fibroblasts. Exp Hematol 36:642–654PubMedCrossRefGoogle Scholar
  33. 33.
    Corticchiato O, Cajot JF, Abrahamson M, Chan SJ, Keppler D, Sordat B (1992) Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int J Cancer 52:645–652PubMedCrossRefGoogle Scholar
  34. 34.
    Konduri SD, Yanamandra N, Siddique K, Joseph A, Dinh DH, Olivero WC, Gujrati M, Kouraklis G, Swaroop A, Kyritsis AP, Rao JS (2002) Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 21:8705–8712PubMedCrossRefGoogle Scholar
  35. 35.
    Wai Wong C, Dye DE, Coombe DR (2012) The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol 2012:340296PubMedGoogle Scholar
  36. 36.
    Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, Fallague K, Schiff C, Dignat-George F, Vely F, Leroyer AS (2013) The involvement of CD146 and its novel ligand galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem 288:2571–2579PubMedCrossRefGoogle Scholar
  37. 37.
    Leitzmann MF, Rohrmann S (2012) Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol 4:1–11PubMedGoogle Scholar
  38. 38.
    Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA (2010) American cancer society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60:70–98PubMedCrossRefGoogle Scholar
  39. 39.
    Cho E, Rosner BA, Feskanich D, Colditz GA (2005) Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 23:2669–2675PubMedCrossRefGoogle Scholar
  40. 40.
    Dean DS, Hay ID (2000) Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 7:229–239PubMedGoogle Scholar
  41. 41.
    Mazzaferri EL, Kloos RT (2001) Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447–1463PubMedCrossRefGoogle Scholar
  42. 42.
    Ma X, Liu J, Wu J, Yan X, Wu P, Liu Y, Li S, Tian Y, Cao Y, Chen G, Meng L, Xu G, Wang S, Lu Y, Ma D, Zhou J (2010) Synergistic killing effect between vorinostat and target of CD146 in malignant cells. Clin Cancer Res 16:5165–5176PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Tulane University Health Sciences CenterNew OrleansUSA
  2. 2.Urology DepartmentTulane University School of MedicineNew OrleansUSA
  3. 3.Biology DepartmentFaculty of Science, Helwan UniversityCairoEgypt
  4. 4.Tulane University School of MedicineNew OrleansUSA

Personalised recommendations